Alnylam Is Down ~58%-Opportunity for a TTR Leader, or an Expectation Trap?

Alnylam's drop looks more like a confidence reset than a settled fundamentals break

Alnylam looks interesting here, but only if the selloff reflects shattered expectations more than a broken business. After a 52-week high of $491.22, the stock had fallen to about $205.48 - roughly 58% off the peak. Then came the Q2 report: Alnylam posted $1.172 billion in Q2 product revenue, but also revises full-year 2026 TTR net product revenue guidance from $4,400 to $4,700 million to $4,200 to $4,500 million. The market reacted hard, with the stock down 28.3% to $205.52 following a Q2 2026 earnings miss and lowered 2026 sales guidance.

That makes the current setup less about whether Alnylam is growing and more about whether trust can rebuild fast enough to stop a sharp multiple reset from becoming permanent.

Q1 set a hypergrowth bar that made Q2 look slow by comparison

Alnylam's commercial engine did not break. Its growth simply stopped matching the market's new baseline.

The market anchored on Q1's outlier pace

In Q1, Alnylam delivered $1.036 billion in product revenue, up 121%, while TTR grew 153%. That kind of surge can lift sentiment quickly, but it can also raise the bar unrealistically. Once investors treat an outlier quarter as a new baseline, strong growth can start to feel like deceleration.

Q2 did not produce weak numbers. Alnylam still posted $1.172 billion in Q2 product revenue, up 74%, driven by $1,030 Million (89% Growth Compared with Q2 2025) in TTR. But after Q1, the market was no longer asking whether the franchise was working. It was asking whether the step-change could continue. The guidance cut shifted the conversation from still-high growth to whether the best upside had already shown up.

The TTR franchise is still doing the core job

The bull case still starts with execution. In Q2, Alnylam generated $1,030 Million (89% Growth Compared with Q2 2025) in TTR revenue, and the company said that quarter marked over $1 billion in TTR revenues. That supports the basic case that TTR is not a one-quarter story.

Vutrisiran also still has a credible heart-franchise narrative. The drug showed a 33% reduction in deaths and heart-failure hospitalizations, and company materials presented at ACC.26 further support use of vutrisiran as first-line treatment for ATTR-CM. Even after the disappointed optics, that leaves Alnylam with a defensible position in the ATTR-CM discussion investors cared most about.

Reuters captured the expectation gap, not a collapse in the biology

The heart-data disappointment followed the same pattern as the revenue story: strong signal, weaker market optics.

Reuters reported that vutrisiran help reduce the number of deaths and heart issue-related hospitalizations by 33%, but also that the detailed data showed that the drug, in combination with other treatments, reduced the risk of death through 36 months. It reduced the risk of death by 30% when tested alone, but this was not statistically significant. Investors had been looking for a cleaner win after the stock had already run. Instead, they got data that supported commercial promise but did not fully settle the expansion debate.

That is why the stock action was so brutal. The market was not reacting to weak biology. It was reacting to a narrative gap between what had been priced in and what was finally proven.

What would bring the bull case back

Alnylam does not need a perfect quarter to recover. It needs the market to shift from treating this as a broken momentum story to treating it as an expanding TTR platform with normal execution risk.

Signals that the market may be stabilizing

• Management pairs the revised TTR outlook with clear commercial messaging rather than forcing investors to infer the story.
• The company continues to highlight that Q2 marked over $1 billion in TTR revenues, reinforcing that the franchise is still scaling.
• Heart-franchise updates keep supporting the earlier 33% reduction in deaths and heart-failure hospitalizations without inviting fresh disappointment from heightened expectations.
• Pipeline and commercialization developments - including Phase 2 Initiations of ALN-6400 in Von Willebrand Disease and Mivelsiran in Down Syndrome-Associated Alzheimer's Disease - help the story look broader than a single expectation miss.

Is this a buying opportunity or a trap?

Near term, this still looks like a reaction setup rather than a fully confirmed rebound. Alnylam was trading near its 52-week low of $205.48, with support at $198 and resistance at $213. That makes it vulnerable to another shakeout if trust continues to deteriorate.

The opportunity is real if the market starts viewing Alnylam as a broadening TTR leader with meaningful pipeline upside. The trap is real if investors keep treating 74% revenue growth and a >$1 billion TTR quarter as evidence of a peak that has already passed.

For now, the evidence supports a cautious stance: the franchise still looks strong, but the stock may need time before fear stops dominating the tape.